Verve Therapeutics (VERV) Competitors $11.26 +0.06 (+0.49%) As of 10:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERV vs. RYTM, PTCT, CYTK, ACAD, MRUS, SWTX, RNA, ACLX, RARE, and PTGXShould you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Cytokinetics (CYTK), ACADIA Pharmaceuticals (ACAD), Merus (MRUS), SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), Arcellx (ACLX), Ultragenyx Pharmaceutical (RARE), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Verve Therapeutics vs. Its Competitors Rhythm Pharmaceuticals PTC Therapeutics Cytokinetics ACADIA Pharmaceuticals Merus SpringWorks Therapeutics Avidity Biosciences Arcellx Ultragenyx Pharmaceutical Protagonist Therapeutics Rhythm Pharmaceuticals (NASDAQ:RYTM) and Verve Therapeutics (NASDAQ:VERV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment. Which has more volatility & risk, RYTM or VERV? Rhythm Pharmaceuticals has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500. Do analysts prefer RYTM or VERV? Rhythm Pharmaceuticals currently has a consensus price target of $77.31, suggesting a potential upside of 15.89%. Verve Therapeutics has a consensus price target of $14.57, suggesting a potential upside of 29.35%. Given Verve Therapeutics' higher possible upside, analysts plainly believe Verve Therapeutics is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00Verve Therapeutics 0 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do insiders and institutionals have more ownership in RYTM or VERV? 97.1% of Verve Therapeutics shares are owned by institutional investors. 6.1% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 19.9% of Verve Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer RYTM or VERV? In the previous week, Rhythm Pharmaceuticals and Rhythm Pharmaceuticals both had 6 articles in the media. Rhythm Pharmaceuticals' average media sentiment score of 0.39 beat Verve Therapeutics' score of -0.01 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verve Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings and valuation, RYTM or VERV? Verve Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$130.13M32.61-$260.60M-$2.81-23.74Verve Therapeutics$32.33M31.06-$198.71M-$2.11-5.34 Is RYTM or VERV more profitable? Rhythm Pharmaceuticals has a net margin of -123.26% compared to Verve Therapeutics' net margin of -303.64%. Verve Therapeutics' return on equity of -35.81% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-123.26% -739.62% -44.27% Verve Therapeutics -303.64%-35.81%-27.57% SummaryVerve Therapeutics beats Rhythm Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERV vs. The Competition Export to ExcelMetricVerve TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.00B$2.43B$5.50B$9.00BDividend YieldN/A1.77%5.39%4.10%P/E Ratio-5.348.8826.5720.02Price / Sales31.06672.33415.46120.95Price / CashN/A151.5836.1356.90Price / Book1.934.618.065.50Net Income-$198.71M$31.16M$3.15B$248.50M7 Day Performance0.04%0.51%1.72%2.61%1 Month Performance132.75%7.63%3.92%5.42%1 Year Performance119.16%1.44%35.02%20.76% Verve Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERVVerve Therapeutics3.3152 of 5 stars$11.27+0.5%$14.57+29.4%+124.2%$1.00B$32.33M-5.34110RYTMRhythm Pharmaceuticals3.8053 of 5 stars$62.13+0.2%$76.62+23.3%+58.1%$3.95B$130.13M-22.11140PTCTPTC Therapeutics4.4282 of 5 stars$49.60-1.2%$65.00+31.0%+61.7%$3.93B$806.78M7.621,410Analyst RevisionCYTKCytokinetics4.2945 of 5 stars$32.64+0.6%$70.92+117.3%-37.3%$3.90B$18.47M-6.17250Positive NewsACADACADIA Pharmaceuticals4.6956 of 5 stars$22.48-1.0%$27.64+23.0%+34.1%$3.76B$957.80M16.41510MRUSMerus1.8524 of 5 stars$52.74-0.7%$84.64+60.5%+0.5%$3.65B$36.13M-12.9337SWTXSpringWorks Therapeutics1.558 of 5 stars$46.97+0.0%$52.57+11.9%N/A$3.54B$219.67M-13.77230RNAAvidity Biosciences2.1929 of 5 stars$29.15-0.5%$66.56+128.3%-24.3%$3.51B$10.90M-9.72190ACLXArcellx2.8121 of 5 stars$63.62+1.0%$111.23+74.8%+24.6%$3.51B$107.94M-21.2880Positive NewsRAREUltragenyx Pharmaceutical4.0584 of 5 stars$36.83-0.8%$87.00+136.2%-3.7%$3.48B$560.23M-6.261,294News CoveragePTGXProtagonist Therapeutics1.8906 of 5 stars$53.36+0.0%$66.10+23.9%+46.5%$3.31B$434.43M71.15120 Related Companies and Tools Related Companies Rhythm Pharmaceuticals Competitors PTC Therapeutics Competitors Cytokinetics Competitors ACADIA Pharmaceuticals Competitors Merus Competitors SpringWorks Therapeutics Competitors Avidity Biosciences Competitors Arcellx Competitors Ultragenyx Pharmaceutical Competitors Protagonist Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VERV) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
